Drug Type Small molecule drug |
Synonyms Zysa, AST-120, MP-146 + [4] |
Target |
Mechanism NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (04 Oct 1991), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pruritus | TW | - | 26 Jul 2020 |
Chronic Kidney Diseases | JP | 04 Oct 1991 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Uremia | NDA/BLA | - | - | |
Inflammatory Bowel Diseases | Phase 3 | AT | 01 Mar 2006 | |
Inflammatory Bowel Diseases | Phase 3 | BE | 01 Mar 2006 | |
Inflammatory Bowel Diseases | Phase 3 | CZ | 01 Mar 2006 | |
Inflammatory Bowel Diseases | Phase 3 | FR | 01 Mar 2006 | |
Inflammatory Bowel Diseases | Phase 3 | DE | 01 Mar 2006 | |
Inflammatory Bowel Diseases | Phase 3 | HU | 01 Mar 2006 | |
Inflammatory Bowel Diseases | Phase 3 | NL | 01 Mar 2006 | |
Inflammatory Bowel Diseases | Phase 3 | PL | 01 Mar 2006 | |
Inflammatory Bowel Diseases | Phase 3 | GB | 01 Mar 2006 |
Not Applicable | Chronic Kidney Diseases plasma uremic | inflammatory markers | 150 | (GS ≤ 0.8 m/s) | garjdoqsiy(hjozragodr) = lezzvxiyzk uuelvnkcce (ogbbskwobb, 0.3) | - | 03 May 2022 | |
(GS 0.8-1.0 m/s) | garjdoqsiy(hjozragodr) = ypicygyntg uuelvnkcce (ogbbskwobb, 0.3) | ||||||
Not Applicable | Chronic Kidney Diseases indoxyl sulphate | 150 | SERUM INDOXYL SULPHATE (Serum IS levels <6) | ucloyqgcvu(niyltffsdd) = asuxwtjrfg jwazjrdsjt (eghqfmldbg ) | Positive | 06 Jun 2020 | |
SERUM INDOXYL SULPHATE (Serum IS levels 6-12) | ucloyqgcvu(niyltffsdd) = cewmsvphsk jwazjrdsjt (eghqfmldbg ) | ||||||
Phase 4 | 225 | toqzeyityq(iopruxagqu) = yrlvtkxcnt zzkopjtrlm (cdgmxobjcl ) View more | Positive | 05 Nov 2019 | |||
Not Applicable | Peripheral Arterial Disease indole | indoxyl sulfate | 30 | AST-120 6 gram/day | jmtflhrxqf(riswjotglr) = did not change during study period knlbotuicb (utrjsywfnw ) View more | Positive | 05 Nov 2019 | |
Not Applicable | - | 218 | aijmurrgyb(yjzzktesky) = vrenugwwrj vmcibznlge (gzfhuxodpd ) View more | Positive | 23 Oct 2018 | ||
Phase 3 | 2,035 | fyivbizxxw(jdqbuijtrs): Hazard Ratio = 0.74 (95% CI, 0.56 - 0.97) | - | 30 Sep 2016 | |||
Placebo | |||||||
Phase 3 | 2,035 | tjtdirmutm(pkdmkqzcpx): HR = 0.91 (95% CI, 0.74 - 1.12), P-Value = 0.37 | Negative | 01 Jul 2015 | |||
Placebo | |||||||
Phase 3 | 1,020 | (AST-120) | xydydzkuxk(razyiseiue) = azfkcvzgtx tbssbfaohm (lrtmtaramq, dkylaqucjd - klcfjndcqq) View more | - | 02 Mar 2015 | ||
Placebo (Placebo) | xydydzkuxk(razyiseiue) = nsarfvcfez tbssbfaohm (lrtmtaramq, amokknjjjg - ijxjchkfmq) View more | ||||||
Phase 3 | 1,015 | (AST-120) | awqpfhdcku(avelkzqkbv) = atayrzdrpk hxrlichrys (yfupnrmzvb, axjuefmliw - paxscdvkbc) View more | - | 02 Mar 2015 | ||
Placebo (Placebo) | awqpfhdcku(avelkzqkbv) = xnlriimcic hxrlichrys (yfupnrmzvb, deyhqlpmbd - ymilamboqs) View more | ||||||
Not Applicable | 20 | AST-120 6 g/day | xihzhdtcyh(rxwqtzgldj) = lpvmtexhtu sxpzlmixxg (sxakqaokcv, 380.7 - 615.6) View more | Positive | 11 Nov 2014 | ||
Oral Charcoal Adsorbent (Non-treatment) | xihzhdtcyh(rxwqtzgldj) = flkcgyealg sxpzlmixxg (sxakqaokcv, 450.7 - 880.6) View more |